GlassScriptPhysician profile
Julie A Utendorf
NPI 1437158839
$2,394.01
in general payments reported to CMS, 2019-2025
22 companies · $529 in 2025
The $529 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $536 · 2020: $101 · 2023: $559 · 2024: $669 · 2025: $529.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,757.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,757.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $564.91 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Novo Nordisk INC | $434.11 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $197.50 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Lilly USA, LLC | $180.12 | 2019-2025 | Mounjaro, Zepbound |
| Pfizer INC. | $140.70 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $117.84 | 2019-2024 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $86.39 | 2023-2024 | |
| Astellas Pharma US INC | $82.71 | 2019-2025 | Veozah |
| Abbott Laboratories | $79.40 | 2024-2025 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $78.67 | 2019-2023 | Bexsero |
| Amgen INC. | $78.61 | 2019-2023 | Otezla, Repatha, Evenity |
| Otsuka America Pharmaceutical, INC. | $67.38 | 2023-2025 | Rexulti |
| Axsome Therapeutics, INC. | $57.71 | 2024-2025 | Auvelity |
| Merck Sharp & Dohme LLC | $45.20 | 2023-2024 | Gardasil 9, Capvaxive, Gardasil |
| Amarin Pharma, INC. | $43.15 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $29.00 | 2023-2024 | Cologuard Collection Kit |
| Dynavax Technologies Corporation | $26.81 | 2025 | Heplisav-B |
| Alnylam Pharmaceuticals INC. | $26.50 | 2024 | Onpattro |
| Lundbeck LLC | $15.46 | 2024 | Vyepti |
| Genentech USA, INC. | $15.17 | 2020 | |
| Sanofi-Aventis U.S. LLC | $13.86 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $12.81 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julie Utendorf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.